Lausanne-based HealthTech startup ReproNovo, an organization innovating therapies for reproductive medication and girls’s well being, has secured a €57 million Sequence A financing spherical.
The spherical was led by Jeito Capital, AXA IM and M Ventures, alongside a syndicate of healthcare funds together with Ysios Capital and ALSA Ventures.
Jean Marie Duvall, Co-founder and CEO of ReproNovo, stated: “We’re targeted on modern therapeutic options for female and male infertility and pioneering administration choices for situations like adenomyosis. Our intention is to deal with important gaps within the panorama of infertility and girls’s well being worldwide. We’re thrilled to announce the profitable closing of our $65 million Sequence A funding spherical with this robust, sector specialised group of buyers, marking a major milestone in our journey to changing into a number one reproductive medication and girls’s well being firm.”
Based in 2021, ReproNovo is growing novel approaches to deal with important gaps in reproductive medication and girls’s well being, together with female and male infertility in addition to uterine well being. The corporate, led by Jean Marie Duvall (CEO) Joan-Carles Arce, MD, PhD (CSO and Medical Officer), and BingMei Hao (CFO), convey a monitor document in scientific improvement and business launches.
Since its inception, ReproNovo has constructed a pipeline comprising two Part 2 clinical-stage property throughout three illness areas. The corporate plans to make use of the proceeds from this financing to advance this pipeline throughout a number of programmes:
- With its lead candidate, RPN-001 (leflutrozole), the corporate will deal with the event of an oral remedy for male infertility on account of low testosterone ranges. In keeping with ReproNovo, low testosterone is changing into extra prevalent, together with in youthful males, highlighting the necessity for an efficacious therapy possibility. This pattern coincides with a broader decline in male reproductive well being, now recognised as a public health problem.
- RPN-002 (nolasiban), additionally orally administered remedy, is a “first-in-class” compound to handle adenomyosis, an overgrowth of endometrial tissue into the uterus that may end up in extreme menstrual bleeding and ache. Much like endometriosis, this can be a frequent gynecological situation, with recent imaging studies figuring out options of adenomyosis in almost one in 4 ladies present process gynecological analysis.
RPN-002 may even be explored for bettering success charges in assisted reproductive applied sciences (ART).
Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, stated: “ReproNovo combines robust modern potential, a seasoned crew, and a transparent ambition to deal with some of the urgent international challenges of our time: declining beginning charges. At Jeito, we’re dedicated to advancing breakthrough improvements with vital worth for each sufferers and society. This funding displays that dedication. We’re proud to assist the acceleration of ReproNovo’s scientific improvement and assist unlock its potential to develop into a future market chief.”
The worldwide decline in fertility charges, coupled with the rising incidence of male infertility (sperm counts have fallen by 50% to 60% over the last four decades) and the numerous well being dangers ladies endure throughout fertility therapies underscore the necessity for modern reproductive options that tackle each genders and these international challenges comprehensively.
Ksenija Pavletic, Companion and Chief Business Officer at Jeito Capital, added: “As roughly one in six individuals worldwide will face infertility points, we’re proud to assist ReproNovo, whose dedication to advancing novel therapies in reproductive well being aligns effectively with our deal with accelerating cutting-edge applied sciences and the commercialisation of therapies with transformative advantages for sufferers. We’re extremely impressed by the ReproNovo crew, whose members have a powerful monitor document on this discipline, having introduced numerous compounds efficiently by means of scientific improvement and onto the market. Their deep understanding of the sector will allow them to successfully tackle important unmet wants which have a powerful impression on society.”
Whereas headquartered in Lausanne, Switzerland, the corporate has its main improvement crew in Copenhagen, Denmark, and a further improvement web site in Barcelona, Spain.
Adjoining to this announcement, Ksenija Pavletic, Jeito Companion and Chief Business Officer with 25 years of expertise in reproductive medication and girls’s well being, may even be becoming a member of ReproNovo’s Board of Administrators.
